Evasion of Cell Senescence Leads to Medulloblastoma Progression
Lukas Tamayo-Orrego,
Chia-Lun Wu,
Nicolas Bouchard,
Ahmed Khedher,
Shannon M. Swikert,
Marc Remke,
Patryk Skowron,
Michael D. Taylor,
Frédéric Charron
Affiliations
Lukas Tamayo-Orrego
Molecular Biology of Neural Development, Institut de Recherches Cliniques de Montréal, 110 Pine Avenue West, Montreal, QC H2W 1R7, Canada
Chia-Lun Wu
Molecular Biology of Neural Development, Institut de Recherches Cliniques de Montréal, 110 Pine Avenue West, Montreal, QC H2W 1R7, Canada
Nicolas Bouchard
Molecular Biology of Neural Development, Institut de Recherches Cliniques de Montréal, 110 Pine Avenue West, Montreal, QC H2W 1R7, Canada
Ahmed Khedher
Molecular Biology of Neural Development, Institut de Recherches Cliniques de Montréal, 110 Pine Avenue West, Montreal, QC H2W 1R7, Canada
Shannon M. Swikert
Molecular Biology of Neural Development, Institut de Recherches Cliniques de Montréal, 110 Pine Avenue West, Montreal, QC H2W 1R7, Canada
Marc Remke
Research Group “Non-coding RNAs in Pediatric Cancers,” German Cancer Consortium, University Hospital Düsseldorf, Department of Pediatric Oncology, Hematology, and Clinical Immunology, 40225 Düsseldorf, Germany
Patryk Skowron
Division of Neurosurgery and The Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada
Michael D. Taylor
Division of Neurosurgery and The Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada
Frédéric Charron
Molecular Biology of Neural Development, Institut de Recherches Cliniques de Montréal, 110 Pine Avenue West, Montreal, QC H2W 1R7, Canada
How brain tumors progress from precancerous lesions to advanced cancers is not well understood. Using Ptch1+/− mice to study medulloblastoma progression, we found that Ptch1 loss of heterozygosity (LOH) is an early event that is associated with high levels of cell senescence in preneoplasia. In contrast, advanced tumors have evaded senescence. Remarkably, we discovered that the majority of advanced medulloblastomas display either spontaneous, somatic p53 mutations or Cdkn2a locus inactivation. Consistent with senescence evasion, these p53 mutations are always subsequent to Ptch1 LOH. Introduction of a p53 mutation prevents senescence, accelerates tumor formation, and increases medulloblastoma incidence. Altogether, our results show that evasion of senescence associated with Ptch1 LOH allows progression to advanced tumors.